Advances in Hematology / 2009 / Article / Tab 1 / Review Article
Aspirin Resistance Table 1 Prevalence of aspirin resistance.
Reference Patients Test used Prevalence of AR Comments N (%)Christiaens et al. [32 ]
PFA-100 analyzer 29 (29.9)
(38 versus 15%)
Stable CAD patients already on aspirin No clinical correlation with laboratory parameters after 2.5 years follow-up
Pamukcu et al. [33 ]
PFA-100 analyzer 52 (22.2) Similar risk in resistant and nonresistant patients after
months follow-up. Risk in aspirin resistant patients increased after cessation of clopidogrel
Stable CAD Pamukcu et al. [34 ]
PFA-100 analyzer 20 (19) Greater risk of MACE in patients resistant to aspirin ACS
Akay et al. [35 ]
Optical platelet aggregometry 77 (27.5) Large trial evaluating the frequency of AR in healthy subjects Healthy Turkish volunteers (ADP, AA)
Lee et al. [36 ]
VerifyNow-Aspirin 128 (27.4) 100 mg or less daily dose were associated with a higher incidence of AR in patients with CAD Stable CAD Harrison et al. [30 ]
PFA-100 22 (22) Poor agreement between the different tests leads to the conclusion that aspirin resistance is highly test-specific Patients after TIA or Stroke VerifyNow-Aspirin 17 (17) Optical platelet aggregometry 5 (5) Gum et al. [28 ]
Optical platelet aggregometry 18 (5.5) Trend toward increased age in patients with AR Stable CAD PFA-100 analyzer 31 (9.5)
AR: aspirin resistance; CAD: coronary artery disease; ACS: acute coronary syndrome; MACE: major adverse cardicac events; ADP: adenosine diphosphate; AA: arachidonic acid; TIA: transient ischemic attack.
